Toxicity Profile of Panobinostat as seen in the PANORAMA Trial

Andrzej Jakubowiak, MD, PhD
Published Online: August 22, 2014
Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.

Clinical Pearls:
  • In the PANORAMA trial, there was a higher proportion of GI toxicities in the panobinistat arm compared to the placebo arm.
  • A higher rate of thrombocytopenia and other hematological toxicities were also seen in the panobinostat arm.
  • However, all of the toxicities were mostly manageable and did not impact the outcome of the trial.
  • More details are needed to get a better understanding of the toxicity profile of this combination in this setting.


Related Articles
Denise A. Yardley, MD, from Sarah Cannon Research Institute, discusses toxicities associated with treatment with PI3K inhibitors for breast cancer.
Anti-CD38 monoclonal antibodies continue to demonstrate promise and generate excitement that a new treatment paradigm could be on the horizon for patients with multiple myeloma.
Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses the results of the phase III ASPIRE trial.
Immunotherapy is the only alternative to chemotherapy and radiation for the treatment of advanced-stage tumors and recent research has shown a correlation between weight and the toxicity of these immunotherapies.
JTT Articles
Graft Versus Host Disease for the General Oncologist
HPV Test With Genotyping Supplants Pap Test
Management of Hepatocellular Cancer
External Resources

AJMC
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.